A randomised, placebo-controlled, Phase II trial of adjuvant Avelumab in patients with stage I-III Merkel cell carcinoma

I-MAT will determine if a six-month treatment regime of Avelumab is well-tolerated and can eliminate residual microscopic cancer cells, thus reducing the risk of the cancer reoccurring and improving the overall outcomes for patients with early-stage Merkel cell carcinoma.

Primary Sponsor

Melanoma and Skin Cancer Trials Limited (MASC Trials)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG)

Accrual Target

132

Expected Date of Accrual

June 2024

Trial Chairperson

Dr Wen Xu, Princess Alexandra Hospital, QLD, Australia

Trial Contact

imat@masc.org.au

Related Post

Tour de Cure grants for TROG Cancer Research trials
9 January, 2025

Tour de Cure grants support two valuable TROG trials

9 January 2025: Two important TROG Cancer Research trials

7 January, 2025

GenesisCare Foundation $300,000 donation to support TROG work

7 January 2025: TROG Cancer Research is advancing vital